Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
$2.78
-5.1%
$5.93
$2.73
▼
$11.15
$26.02M1.69241,164 shs286,377 shs
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$2.74
-1.1%
$3.13
$2.65
▼
$6.92
$24.72M0.61137,516 shs46,577 shs
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$3.83
-4.3%
$5.18
$8.50
▼
$23.00
$23.95MN/A37,647 shs20,072 shs
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
$0.01
+1.5%
$0.02
$0.01
▼
$0.10
$6.03M-0.1460,984 shs479,008 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
0.00%-8.85%-45.91%-66.83%-74.69%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
0.00%-8.67%-2.14%-17.96%-54.64%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00%-9.09%-13.04%-31.27%-73.65%
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
0.00%-5.71%-26.67%-69.72%-86.09%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
$2.78
-5.1%
$5.93
$2.73
▼
$11.15
$26.02M1.69241,164 shs286,377 shs
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$2.74
-1.1%
$3.13
$2.65
▼
$6.92
$24.72M0.61137,516 shs46,577 shs
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$3.83
-4.3%
$5.18
$8.50
▼
$23.00
$23.95MN/A37,647 shs20,072 shs
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
$0.01
+1.5%
$0.02
$0.01
▼
$0.10
$6.03M-0.1460,984 shs479,008 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
0.00%-8.85%-45.91%-66.83%-74.69%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
0.00%-8.67%-2.14%-17.96%-54.64%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00%-9.09%-13.04%-31.27%-73.65%
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
0.00%-5.71%-26.67%-69.72%-86.09%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
2.89
Moderate Buy$37.801,259.71% Upside
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
2.60
Moderate Buy$11.25310.58% Upside
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00
N/AN/AN/A
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest OTLC, ACET, EVAX, and IZTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/6/2026
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
Reiterated RatingSell (D-)
9/29/2026
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
Reiterated RatingBuy
9/28/2026
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
Reiterated RatingOutperform$25.00 ➝ $28.00
9/28/2026
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
Boost Price TargetBuy$27.00 ➝ $34.00
9/18/2026
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
Reiterated RatingBuy$27.00
9/1/2026
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
UpgradeStrong-Buy
8/21/2026
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
Reiterated RatingSell (D-)
(Data available from 11/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
N/AN/AN/AN/A$16.62 per shareN/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$7.53M3.28N/AN/A$2.04 per share1.34
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/A
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
$70K86.08$0.66 per share0.02$0.59 per share0.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
-$116.80M-$8.57N/AN/AN/AN/A-69.71%-56.97%N/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
-$7.71M-$1.21N/AN/AN/AN/A-61.43%-34.23%11/19/2026 (Estimated)
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
$249.28M$0.590.02N/AN/AN/A123.75%81.36%N/A

Latest OTLC, ACET, EVAX, and IZTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/19/2026Q3 2026
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
-$0.01N/AN/AN/A$0.30 millionN/A
11/5/2026Q3 2026
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
-$1.56-$1.76-$0.20-$1.76N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
N/AN/AN/AN/AN/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
N/AN/AN/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/A
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
0.01
6.09
6.09
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
0.69
5.06
5.06
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/A
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
0.01
0.08
0.08

Institutional Ownership

CompanyInstitutional Ownership
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
83.89%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
11.04%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
3.40%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
41.64%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
39.22%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
1029.36 million9.04 millionOptionable
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
469.02 million5.27 millionNo Data
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
296.25 millionN/AN/A
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
41456.49 million277.46 millionNot Optionable

Recent News About These Companies

OTLC Share News Today

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adicet Bio stock logo

Adicet Bio NASDAQ:ACET

$2.78 -0.15 (-5.12%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$2.78 +0.01 (+0.18%)
As of 11/13/2026 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Evaxion A/S stock logo

Evaxion A/S NASDAQ:EVAX

$2.74 -0.03 (-1.08%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$2.74 +0.00 (+0.18%)
As of 11/13/2026 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Invizyne Technologies stock logo

Invizyne Technologies NASDAQ:IZTC

$3.83 -0.17 (-4.25%)
As of 11/13/2026

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Oncotelic Therapeutics stock logo

Oncotelic Therapeutics OTCMKTS:OTLC

$0.01 +0.00 (+1.54%)
As of 11/13/2026 03:15 PM Eastern

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.